Turmeric for Fatty Liver and Metabolic Syndrome
Fatty liver disease is the quiet centre of metabolic syndrome. It affects something like a quarter to a third of adults worldwide, it usually produces no symptoms at all, and it is discovered by accident — an ultrasound ordered for something else, or a liver enzyme that came back mildly high on a routine panel. Most people who have it do not know.
Several small randomised trials report that turmeric improves it: less fat visible on ultrasound after eight weeks, lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST), better lipids and glucose alongside. Those trials are real and this page takes them seriously. It also takes seriously that they are small, short, run mostly in Iran and Thailand, and measured by ultrasound — a crude, operator-dependent way of grading liver fat that almost no modern hepatology trial would rely on as a primary endpoint.
One more thing is stated here at the top and repeated at the bottom: weight loss and dietary change are the treatment for fatty liver. Losing a meaningful fraction of body weight does more for a fatty liver than anything in this literature, and nothing here displaces it. This page is about a possible small addition to that, not a substitute for it.
This article covers the non-alcoholic fatty liver disease (NAFLD) and metabolic-syndrome trial evidence specifically. For turmeric's broader relationship with the liver — bile flow, traditional use, the liver's role in processing curcumin, and the detoxification claims — see Turmeric and Liver Health.
Table of Contents
- What Fatty Liver Actually Is
- Why It Matters When It Has No Symptoms
- Metabolic Syndrome: The Five-Part Diagnosis
- Rahmani 2016: The Ultrasound Trial
- Panahi 2017: Phytosomal Curcumin
- Panahi 2019: Curcuminoids Plus Piperine
- Saberi-Karimian 2020: The Inflammation Question
- Yaikwawong 2025: Steatosis in Obesity and Diabetes
- The Anthropometric Meta-Analysis
- The Ultrasound Problem
- Adipokines: Fat Tissue as an Endocrine Organ
- Diet and Weight Remain the Treatment
- The Uncomfortable Irony
- Cautions
- Key Research Papers
- Connections
- Featured Videos
What Fatty Liver Actually Is
Your liver is supposed to contain a small amount of fat. When more than about five percent of its weight is fat, and alcohol is not the cause, you have non-alcoholic fatty liver disease. Under the nomenclature adopted in 2023 the condition is increasingly called metabolic dysfunction-associated steatotic liver disease (MASLD), a renaming that put the metabolic cause in the name instead of defining the disease by what it is not. Older papers, including every trial on this page, use non-alcoholic fatty liver disease.
The picture to hold is a liver that has quietly turned from deep red-brown to pale and greasy, its cells stuffed with droplets of triglyceride. It happens when the liver takes in or manufactures more fat than it can burn or export. Insulin resistance is the usual engine: insulin normally tells fat cells to hold on to their stores, and when that signal fails, fatty acids pour into the bloodstream and the liver mops them up. Excess fructose and refined carbohydrate add to the problem from the other end, because the liver converts them directly into fat.
The condition exists on a spectrum, and where a person sits on it matters far more than the label:
- Simple steatosis. Fat in the liver, no meaningful inflammation or cell injury. Common, usually stable, and reversible.
- Steatohepatitis (non-alcoholic steatohepatitis, NASH, now called MASH, metabolic dysfunction-associated steatohepatitis). Fat plus inflammation plus injury to liver cells. This is the version that progresses, and diagnosing it properly has historically required a biopsy.
- Fibrosis. The liver responds to persistent injury by laying down scar tissue. Fibrosis stage is the single strongest predictor of how someone will fare over the long run.
- Cirrhosis. Scarring extensive enough to distort the liver's architecture and impair its function. Largely irreversible, and it carries a risk of liver cancer and liver failure.
This distinction is essential for reading the trials below. Most of them enrolled people with fat on ultrasound — the first and mildest rung of the ladder. None of them used a liver biopsy, so none established anything about inflammation on biopsy, fibrosis stage or progression to cirrhosis. Only one, the 2025 Yaikwawong trial, measured liver fat content and liver stiffness.
Why It Matters When It Has No Symptoms
Fatty liver is almost entirely silent. There may be vague fatigue or a dull fullness under the right ribs, but most people have nothing at all. It is a condition that gets found rather than felt.
It matters for two separate reasons, and the second one surprises people.
The first is the liver itself. A minority of people with fatty liver progress to steatohepatitis, then fibrosis, then cirrhosis, over decades. Fatty liver disease is now among the leading reasons for liver transplantation in wealthy countries, and it is rising as alcohol-related and viral causes fall.
The second reason is more immediately relevant to most people who have it: the commonest cause of death in people with fatty liver is cardiovascular disease, not liver disease. A fatty liver is a visible readout of a metabolic state — insulin resistance, visceral adiposity, atherogenic lipids, chronic low-grade inflammation — that is damaging arteries at the same time it is loading the liver. The liver is the warning light, not the whole engine fault.
That reframing is why fatty liver appears in a section about heart and metabolic health rather than in a section about liver disease. It is also why an intervention that improves the liver picture is interesting beyond the liver — and why improving the picture on an ultrasound is not automatically the same as improving what happens to the person.
Metabolic Syndrome: The Five-Part Diagnosis
Metabolic syndrome is not a disease so much as a named cluster. You are usually said to have it when three or more of the following five are present:
- Central obesity — an enlarged waist circumference, with thresholds that differ by sex and by ethnic background.
- Raised triglycerides, or treatment for them.
- Low high-density lipoprotein (HDL) cholesterol, or treatment for it.
- Raised blood pressure, or treatment for it.
- Raised fasting glucose, or established type 2 diabetes.
Fatty liver is not on the official list, which is a historical accident more than a judgement — it is so tightly bound to the same underlying process that many hepatologists describe it as the hepatic manifestation of metabolic syndrome. Someone with three of the five criteria very often has a fatty liver whether or not anyone has looked.
Why the cluster exists at all comes back to insulin resistance and visceral fat. Fat stored around the organs is not inert padding; it is metabolically active tissue that releases fatty acids straight into the portal vein feeding the liver, along with inflammatory signals and altered hormone output. That single upstream problem produces all five criteria, which is why they travel together and why treating them one number at a time can feel like chasing symptoms.
The turmeric research on metabolic syndrome has concentrated on that upstream biology rather than on the five criteria individually — specifically on inflammatory cytokines and on the hormones fat tissue secretes, the subject of the adipokine section below.
Rahmani 2016: The Ultrasound Trial
The most-cited fatty liver trial appeared in Phytotherapy Research in 2016. It randomised people with ultrasound-diagnosed non-alcoholic fatty liver disease to an amorphous dispersion curcumin formulation (500 mg/day, equivalent to 70 mg of curcumin) or placebo for eight weeks, with liver fat graded by ultrasound before and after.
The headline finding was a marked difference in how many participants improved their ultrasound grade: 78.9% improvement in the curcumin group against 27.5% in the placebo group. Alongside that, the curcumin group showed reductions in alanine aminotransferase and aspartate aminotransferase — the liver enzymes that leak into the blood when liver cells are injured — together with improvements in total cholesterol, low-density lipoprotein (LDL), triglycerides, fasting glucose and body mass index.
The placebo group improving at all is worth noticing, and it is not a flaw. People who enrol in a liver trial tend to change their behaviour: they drink less, eat more carefully, and get weighed regularly by someone who is paying attention. That is precisely why a placebo arm exists, and it is also a reminder of how responsive this condition is to ordinary lifestyle change.
The limitations are the familiar set. Eight weeks is short for a condition that develops over years. The sample was modest. It was a single centre. And the primary endpoint was an ultrasound severity grade, which is the subject of its own section below.
Panahi 2017: Phytosomal Curcumin
A 2017 trial in Drug Research tested a phytosomal curcumin preparation in people with non-alcoholic fatty liver disease over eight weeks, in a larger group than the previous trial.
The formulation is the point of this study. A phytosome binds curcumin to phospholipids — the same class of molecule your cell membranes are built from — producing a complex that is absorbed far more efficiently than plain curcumin powder. The practical consequence is that a phytosomal product delivering a few hundred milligrams of actual curcuminoids can achieve blood levels that plain extract would need many times that dose to approach. When you compare the milligram figures on two turmeric products' labels, you are frequently not comparing the same thing at all.
The trial randomised 102 people with fatty liver on ultrasound to phytosomal curcumin, 1000 mg/day in two divided doses (50 people), or placebo (52 people); 87 completed it, and all received dietary and lifestyle advice before it began. Ultrasound findings improved in 75.0% of the curcumin group against 4.7% of the control group (p < 0.001). Body mass index and waist circumference fell more with curcumin, and aspartate and alanine aminotransferase fell in the curcumin group while they rose in the control group.
The same caveats apply — eight weeks, ultrasound grading, a single research group. There is also a specific safety note that belongs beside the efficacy one: in the 2023 US Drug-Induced Liver Injury Network case series of turmeric-associated liver injury, three of the seven products tested also contained black pepper (piperine), another absorption enhancer, and the authors suggested the rise in cases may reflect increased combination with black pepper. Getting more curcumin into the bloodstream is a double-edged achievement, and it is a peculiar one in a population whose livers are already under strain.
Panahi 2019: Curcuminoids Plus Piperine
A 2019 clinical trial in the Journal of Cellular Biochemistry tested the other common route to better absorption: curcuminoids co-administered with piperine from black pepper, in people with non-alcoholic fatty liver disease.
Piperine works by inhibiting the enzymes in the gut wall and liver that would otherwise conjugate and clear curcumin within minutes of its arrival. The 1998 Shoba study established the size of the effect in human volunteers, and it is dramatic. Because the enzymes involved are the same ones that process a wide range of medications, piperine can also raise the blood levels of other medicines taken at the same time — which makes a turmeric-and-pepper supplement a possible source of drug interactions rather than mere seasoning.
The trial randomised 70 people to 500 mg of curcuminoids with 5 mg of piperine daily, or placebo, for 12 weeks. Ultrasound severity of fatty liver improved with the combination, and the improvement differed significantly from placebo (P = 0.022); the share of patients who improved was only marginally higher than on placebo (P = 0.058). Liver enzymes, cholesterol and low-density lipoprotein cholesterol fell within the curcuminoid group, but apart from albumin these changes did not differ significantly from the placebo group.
No trial on this page compared an absorption-enhanced form with plain extract: Rahmani 2016, Panahi 2017, Panahi 2019 and Saberi-Karimian 2020 each used an enhanced form (an amorphous dispersion, a phytosome, or added piperine).
Saberi-Karimian 2020: The Inflammation Question
A 2020 randomised controlled trial in Complementary Therapies in Medicine asked a more specific and more mechanistic question than the others: what do curcuminoids do to inflammatory status in people with non-alcoholic fatty liver disease?
The question matters because inflammation is what separates the benign form of the disease from the dangerous one. Fat sitting quietly in liver cells does relatively little harm. Fat accompanied by inflammation and cell injury is what drives scarring, and scarring is what determines outcomes. If curcumin genuinely reduces inflammation in a fatty liver, it would be acting on the step that matters rather than on the cosmetic appearance of the organ on a scan.
The trial randomised 55 people with fatty liver to 500 mg of curcuminoids plus 5 mg of piperine daily, or placebo, for 8 weeks, and measured a panel of cytokines and growth factors (interleukins, tumour necrosis factor-alpha, monocyte chemoattractant protein-1, interferon gamma, vascular endothelial growth factor and epidermal growth factor). Weight fell compared with placebo (p = 0.016) and ultrasound severity improved (p = 0.002). The abstract reports improvements in tumour necrosis factor-alpha (p = 0.024), monocyte chemoattractant protein-1 (p = 0.008) and epidermal growth factor (p = 0.0001).
Inflammatory results across this literature have been notably less consistent than the liver-fat findings, and this is the honest place to say so. Circulating inflammatory markers are a blunt instrument: they measure inflammation throughout the whole body, not inflammation inside the liver, and they fluctuate with infections, sleep, exercise, stress and body weight. A trial can show a clear change in liver fat on ultrasound and no clear change in inflammatory markers, and both results can be correct, because the two are measuring different things by different means.
What would settle it is the thing nobody in this literature has done: paired liver biopsies before and after a treatment period long enough to matter. Only one trial, Yaikwawong 2025, has measured liver fat and liver stiffness, over 12 months; none has used biopsy.
Yaikwawong 2025: Steatosis in Obesity and Diabetes
The most recent trial in this collection, published in the International Journal of Molecular Sciences in 2025, examined curcumin and liver steatosis in obese patients with type 2 diabetes — a population carrying the full metabolic load, where fatty liver, insulin resistance and cardiovascular risk all compound one another.
In this 12-month randomised, double-blind, placebo-controlled trial, 227 obese adults with type 2 diabetes took 1500 mg of curcumin daily or placebo. Curcumin significantly reduced liver fat content, liver stiffness and glycated hemoglobin (HbA1c) compared with placebo (all p < 0.001), and lowered the inflammatory signals interleukin-1 beta and tumour necrosis factor-alpha (all p < 0.001). Liver and kidney function tests showed no clinically significant abnormalities, and mild stomach and gut discomfort was the most common non-serious side effect. At 12 months it is far longer than the 8- and 12-week trials above.
The study framed its findings mechanistically, attributing the reduction in liver fat to antioxidant and anti-inflammatory pathways. That framing is consistent with the rest of this leg: the same proposed mechanisms that appear in the blood sugar and endothelial trials reappear here, applied to the liver.
Two observations about where this trial sits. First, it comes from the same Thai research tradition that produced the prediabetes and atherogenic-risk trials described on the blood sugar page — a sustained, coherent research programme, but not independent confirmation of itself. Second, that a group still finds this question worth studying in 2025, more than a decade after the first positive results, tells you the field has not been settled by what came before.
A 2023 updated meta-analysis built on the available evidence from Iran and Thailand (6 earlier systematic reviews and meta-analyses and 16 randomised trials) found that curcumin lowered aspartate aminotransferase by 3.90 units/L and alanine aminotransferase by 5.61 units/L, and that resolution and improvement of fatty liver were more frequent than in control groups (pooled relative risks 3.53 and 3.41). Its authors called for further trials assessing the effect on liver histology, especially non-invasive measures of liver fibrosis and steatosis.
The Anthropometric Meta-Analysis
A 2019 systematic review and meta-analysis in Clinical Nutrition Research asked a narrow question about the whole literature: does turmeric or curcumin supplementation change anthropometric indices — weight, body mass index, waist circumference — in patients with non-alcoholic fatty liver disease?
The question is well chosen, because it is a potential confounder hiding inside every trial on this page. Liver fat responds strongly to weight loss. If the participants taking curcumin also lost weight, then the improvement in their liver might be a consequence of the weight change rather than a direct effect on the liver at all. Those are different claims with different implications, and a trial that does not separate them cannot tell you which one it found.
Anthropometric measures are also the crudest thing in the entire field. A bathroom scale cannot distinguish muscle from fat or subcutaneous fat from visceral fat. Waist circumference is better, and is a genuinely useful proxy for the visceral fat that drives this disease, but it is measured with a tape by a human being and is sensitive to exactly where the tape is placed.
The result was null. Across eight studies (449 participants), the analysis could not show any beneficial effect of turmeric or curcumin on body weight (weighted mean difference -0.54 kg, p = 0.56), body mass index (-0.21 kg/m2, p = 0.39) or waist circumference (-0.88 cm, p = 0.54), with I2 = 0% for all three, and no subgroup showed a significant association. The pooled result gives no sign that weight loss across the trials produced the liver results, although some single trials on this page (Panahi 2017, Saberi-Karimian 2020) did report falls in body mass index or weight compared with placebo. No supplement produces weight change on the scale of a sustained dietary change.
The Ultrasound Problem
Nearly every efficacy claim on this page rests on ultrasound grading of liver fat, and that deserves a candid section of its own.
Ultrasound detects fatty liver because fat scatters sound waves, making the liver look brighter than the kidney next to it. A radiologist grades that brightness, typically as mild, moderate or severe. It is cheap, fast, harmless and available everywhere, which is why it is the standard first test.
It is also a weak research endpoint, for four reasons:
- It is coarse. Three or four categories cannot resolve a change from eighteen percent liver fat to fourteen. A real improvement may not move the grade at all; a trivial one may cross a boundary.
- It is subjective. The grade is a human judgement about image brightness. Two radiologists can disagree about the same scan, and the same radiologist can grade the same liver differently on two occasions.
- It is insensitive at the low end. Ultrasound reliably detects fatty liver only above roughly twenty to thirty percent fat content. Below that it misses it.
- Body habitus degrades it. Image quality falls with increasing body mass — in exactly the population being studied.
Modern hepatology research uses magnetic resonance imaging (MRI) proton-density fat fraction, which measures liver fat as a continuous percentage with excellent reproducibility, or transient elastography, which estimates fat and stiffness together. Neither is exotic; both are standard in trials of drugs being developed for this disease. Their near-total absence from the turmeric literature — the 2025 Yaikwawong trial is the one trial on this page to report liver fat content and liver stiffness — is a real limitation, not a technicality — it is the difference between "the liver looked a bit brighter to a radiologist" and "liver fat fell from eighteen percent to twelve."
None of this means the trials are wrong. It means the evidence is softer than the confident percentages suggest, and that a properly imaged replication would be worth more than another five ultrasound studies.
Liver enzymes in the blood are a second, non-imaging measure. A 2025 GRADE-assessed dose-response meta-analysis of 15 randomised trials (905 participants) found that curcumin significantly reduced alanine aminotransferase (weighted mean difference -4.10) and aspartate aminotransferase (weighted mean difference -3.27), but not alkaline phosphatase (ALP). In the trials of curcumin plus piperine, the effect on alanine aminotransferase and aspartate aminotransferase was not significant.
Adipokines: Fat Tissue as an Endocrine Organ
For most of the twentieth century, fat tissue was regarded as inert storage. That view collapsed in the 1990s with the discovery that fat cells secrete hormones — adipokines — that regulate appetite, insulin sensitivity and inflammation throughout the body. Fat is an endocrine organ, and in metabolic syndrome it is a malfunctioning one.
Two adipokines dominate the research:
Adiponectin improves insulin sensitivity, reduces liver fat production and is anti-inflammatory. Counter-intuitively, it falls as fat mass rises — the more fat tissue you carry, the less of this protective hormone it makes. Low adiponectin tracks with insulin resistance, fatty liver and cardiovascular risk.
Leptin signals satiety to the brain, and rises with fat mass. In obesity the signal is present in abundance but the brain stops responding to it — leptin resistance, a close cousin of insulin resistance. High leptin with continued hunger is the characteristic pattern.
The healthy direction is therefore adiponectin up, leptin down, and several strands of turmeric research have targeted exactly that. A 2016 randomised trial in Nutrition examined curcumin's effect on serum adipokine concentrations. A companion post-hoc analysis published the same year in Biomedicine and Pharmacotherapy examined serum cytokine concentrations in people with metabolic syndrome. A 2024 GRADE-assessed systematic review and meta-analysis in the British Journal of Nutrition pooled the trials measuring circulating adiponectin and leptin, and a 2025 umbrella review in Phytotherapy Research went a level higher, summarising the meta-analyses of curcuminoid effects on serum adipokines.
In the 2016 trial, people with metabolic syndrome took curcumin 1000 mg/day (n = 59) or placebo (n = 58) for 8 weeks; adiponectin rose and leptin fell (both P < 0.001). The 2024 meta-analysis of 13 randomised trials found adiponectin increased (standardised mean difference 0.86) and leptin decreased (standardised mean difference -1.42). The 2025 umbrella review found a substantial increase in adiponectin (standardised mean difference 0.9), rated as moderate-certainty evidence under GRADE, but no significant effect on leptin, where the evidence was rated low.
Two notes on how to read this stack. A post-hoc analysis — a question asked of data after the trial has finished — is hypothesis-generating rather than confirmatory, because with enough measurements something will reach significance by chance. And a GRADE assessment is worth looking for specifically: it is a formal system for rating how much confidence a body of evidence deserves, and in fields like this one it frequently concludes that the certainty is low or very low even where the pooled effect is statistically significant — though the 2025 umbrella review rated the adiponectin evidence moderate. A significant result and a trustworthy result are not the same thing.
Diet and Weight Remain the Treatment
This is the section that matters most, and it would be a disservice to bury it.
Weight loss is the established treatment for fatty liver disease. The relationship is dose-dependent and well documented: losing around three to five percent of body weight reduces liver fat; losing around seven to ten percent improves inflammation and can improve fibrosis. No supplement, turmeric included, has ever demonstrated anything approaching that.
The other measures with real support:
- Less fructose and refined carbohydrate. Sugar-sweetened drinks are the clearest single dietary contributor, because fructose is metabolised almost entirely by the liver and converted directly into fat.
- Less alcohol. Even where alcohol is not the cause, it adds insult to a liver already under strain.
- Exercise, independent of weight loss. Physical activity reduces liver fat even when the scale does not move, by improving insulin sensitivity and increasing the muscle's disposal of glucose and fat.
- A Mediterranean-style dietary pattern has the best evidence of the named patterns, with olive oil, fish, vegetables, legumes and nuts displacing refined carbohydrate.
- Coffee, oddly enough, is associated with less fibrosis in observational studies — consistently enough that hepatologists mention it.
- The conditions that travel with it. Diabetes, lipids and blood pressure are treated in their own right, and some diabetes medications improve liver fat as a side effect.
Since 2024 there is also a liver-directed drug for the advanced form. In the 52-week phase 3 MAESTRO-NASH trial (966 adults with biopsy-confirmed steatohepatitis and fibrosis stage F1B, F2 or F3), steatohepatitis resolved without worsening of fibrosis in 25.9% of patients on resmetirom 80 mg and 29.9% on 100 mg, against 9.7% on placebo, and fibrosis improved by at least one stage in 24.2% and 25.9%, against 14.2%. Diarrhea and nausea were more frequent with resmetirom than with placebo. The US drug label (initial US approval 2024) lists resmetirom, in conjunction with diet and exercise, for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3), under an accelerated approval whose continuation may depend on confirmatory trials.
Where does turmeric sit in that list? At the bottom, as a plausible and low-risk addition for someone already doing the rest. Taking a capsule while the underlying diet and weight are unchanged is unlikely to achieve much, and the trials do not claim otherwise — every one of them was conducted in people who were also being weighed, counselled and followed.
The Uncomfortable Irony
There is a contradiction in this page that is worth stating plainly rather than tucking into a caution list.
Turmeric is being studied as a treatment for liver disease. Turmeric supplements are also a documented cause of liver injury. A 2023 case series in the American Journal of Medicine reported ten cases of hepatotoxicity linked to turmeric products, drawn from the US Drug-Induced Liver Injury Network; five of the patients were hospitalised and one died of acute liver failure. Chemical analysis found turmeric in all 7 products tested, and 3 of them also contained piperine (black pepper). Seven of the 10 patients carried the gene variant HLA-B*35:01 — suggesting that the risk is concentrated in a subset of people who cannot be identified in advance without testing.
The injuries are rare in absolute terms, set against the enormous number of people taking turmeric. But they are real, and turmeric-associated liver injury appears to be rising in the United States: all ten cases were enrolled since 2011, six of them since 2017, which the authors suggest may reflect usage patterns or increased combination with black pepper.
Which leaves an awkward calculation for anyone with a fatty liver. The trials suggest a possible modest improvement in liver fat on ultrasound over eight weeks. The case reports document an uncommon possibility of acute liver injury from the same class of product, and three of the seven products tested in the case series contained black pepper (piperine), the same absorption enhancer used in several of the trials. Both of those things are true at once.
The case series also gives the timing: the injury was typically hepatocellular (damage to the liver cells themselves) and appeared 1 to 4 months after starting. Liver enzymes are measured routinely in people with fatty liver disease, and a rise in the months after starting a concentrated turmeric supplement fits that timing. New yellowing of the skin or eyes (jaundice), dark urine, pale stools or persistent right-upper-abdominal pain are signs of liver injury that hospitals treat as urgent.
Cautions
- Liver injury. The central caution on this page. Uncommon, documented and sometimes severe: in the 2023 case series, five of the ten patients were hospitalised and one died, and three of the seven products tested also contained piperine. The injury typically appeared 1 to 4 months after starting.
- Existing liver disease. In people who already have cirrhosis, hepatitis or an unexplained elevation in liver enzymes, a turmeric-associated injury would add to existing damage; in the case series it was typically hepatocellular, appearing 1 to 4 months after starting.
- Blood thinners. Curcumin inhibits platelet aggregation in the laboratory. Relevant to warfarin, direct oral anticoagulants, clopidogrel and daily aspirin.
- Piperine and prescriptions. Enhanced absorption is not selective; piperine raises blood levels of other drugs handled by the same enzymes.
- Diabetes medication. If it lowers glucose as claimed, combined with insulin or a sulfonylurea it could add to the risk of low blood sugar.
- Gallbladder disease. Turmeric stimulates gallbladder contraction, which raises a concern about concentrated doses for people with gallstones or biliary obstruction.
- Iron. Curcumin chelates iron and may worsen existing iron deficiency at high supplemental doses.
- Surgery. Pre-surgery guidance commonly lists stopping it one to two weeks beforehand and telling the surgical team.
The full treatment is on the Turmeric Safety and Interactions leg. For turmeric's broader relationship with liver physiology, bile and the detoxification claims, see Turmeric and Liver Health.
Key Research Papers
- Rahmani S, Asgary S, Askari G, et al. (2016). Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytotherapy Research. — PubMed PMID: 27270872
- Panahi Y, Kianpour P, Mohtashami R, et al. (2017). Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Drug Research (Stuttgart). — PubMed PMID: 28158893
- Panahi Y, Valizadegan G, Ahamdi N, et al. (2019). Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial. Journal of Cellular Biochemistry. — PubMed PMID: 31168845
- Saberi-Karimian M, Keshvari M, Ghayour-Mobarhan M, et al. (2020). Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Complementary Therapies in Medicine. — PubMed PMID: 32147075
- Yaikwawong M, Kamdee K, Chuengsamarn S. (2025). Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. International Journal of Molecular Sciences. — PubMed PMID: 41096556
- Jafarirad S, Mansoori A, Adineh A, et al. (2019). Does Turmeric/curcumin Supplementation Change Anthropometric Indices in Patients with Non-alcoholic Fatty Liver Disease? A Systematic Review and Meta-Analysis. Clinical Nutrition Research. — PubMed PMID: 31384598
- Panahi Y, Hosseini MS, Khalili N, et al. (2016). Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial. Nutrition. — PubMed PMID: 27297718
- Panahi Y, Hosseini MS, Khalili N, et al. (2016). Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomedicine and Pharmacotherapy. (A post-hoc analysis — hypothesis-generating rather than confirmatory.) — PubMed PMID: 27470399
- Musazadeh V, Abbasi S, Kavyani Z, et al. (2024). The effect of curcumin supplementation on circulating adiponectin and leptin concentration in adults: a GRADE-assessed systematic review and meta-analysis. British Journal of Nutrition. — PubMed PMID: 37980942
- Bahrami LS, Rahnama I, Chambari M, et al. (2025). The Effects of Curcuminoids Supplementation on Serum Adipokines: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials. Phytotherapy Research. — PubMed PMID: 40109154
- Shoba G, Joy D, Joseph T, et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. — PubMed PMID: 9619120
- Nelson KM, Dahlin JL, Bisson J, et al. (2017). The Essential Medicinal Chemistry of Curcumin. Journal of Medicinal Chemistry. — PubMed PMID: 28074653
- Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. (2023). Liver Injury Associated with Turmeric — A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. American Journal of Medicine. — PubMed PMID: 36252717
- Vajdi M, Hassanizadeh S, Hassanizadeh R, Bagherniya M. (2025). Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Nutrition Reviews. — PubMed PMID: 38213188
- Lukkunaprasit T, Tansawet A, Boonmanunt S, et al. (2023). An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand. Scientific Reports. — PubMed PMID: 37037891
- Harrison SA, Bedossa P, Guy CD, et al. (2024). A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine. — PubMed PMID: 38324483
PubMed Topic Searches
- PubMed: Curcumin and non-alcoholic fatty liver disease, randomized trials
- PubMed: Curcumin and metabolic syndrome
- PubMed: MASLD and the renaming of NAFLD
- PubMed: Weight loss and liver fat in fatty liver disease
- PubMed: MRI proton-density fat fraction for liver steatosis
- PubMed: Accuracy of ultrasound grading of hepatic steatosis
- PubMed: Fatty liver disease and cardiovascular mortality
- PubMed: Adiponectin, leptin and insulin resistance
- PubMed: Turmeric-associated hepatotoxicity
Connections
- Turmeric for Heart and Metabolic Health
- Turmeric for Blood Sugar and Type 2 Diabetes
- Turmeric and Cholesterol
- Turmeric, Blood Vessels and Blood Pressure
- Turmeric and Liver Health
- Turmeric
- Turmeric Bioavailability and Forms
- Turmeric Safety and Interactions
- Turmeric for Digestive Health
- Javanese Turmeric
- Black Turmeric
- Culinary and Spice Herbs
- Gut Health
- All Herbs